Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 4/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.47 |
| ▸ | QDPR | P09417 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28574546 | 0.87 | NPC1 (0.42) | TNKSTNKS2P2RY14 | |
| SCHEMBL17210747 | 0.87 | NPC1 (0.42) | TNKSTNKS2P2RY14 | |
| SCHEMBL28538282 | 0.84 | HSP90AA1 (0.40) | P2RY14 | |
| SCHEMBL28572205 | 0.84 | HSP90AA1 (0.44) | — | |
| SCHEMBL18385879 | 0.82 | NPC1 (0.39) | TNKSTNKS2P2RY14 | |
| SCHEMBL18464121 | 0.82 | HSP90AA1 (0.46) | — | |
| SCHEMBL18385877 | 0.82 | NPC1 (0.39) | TNKSTNKS2P2RY14 | |
| SCHEMBL6645441 | 0.81 | SLC18A3 (0.48) | HTR2CSLC18A3SIGMAR1TNKSTNKS2 | |
| SCHEMBL12056677 | 0.79 | NPC1 (0.37) | TNKSTNKS2P2RY14 | |
| SCHEMBL13345627 | 0.79 | NPC1 (0.37) | TNKSTNKS2P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017486-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20220017486-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2022-01-20 | — | — | US | disclosed |
| EP-3888651-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | Kyushu University, National University Corporation (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3888651-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | Kyushu University, National University Corporation (JP) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020111252-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | 国立大学法人九州大学 | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017486-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | DOCK2, DOCK11, DOCK5 | HTR2C 4655/4885SLC18A3 3620/4885SIGMAR1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.